重组人生长激素治疗垂体性侏儒症的临床观察  

Clinical Observation on Treating Growth Hormone Deficiency with Recombinant Human Growth Hormone

作　　者：潘惠茹[1] 张丽娜[1] 龚海红[1] 宫道华[1] 

机构地区：[1]南京医科大学第一附属医院,210029

出　　处：《江苏医药》1998年第7期469-471,共3页Jiangsu Medical Journal

摘　　要：用基因工程重组的人生长激素治疗垂体性侏儒症（GHD）13例6个月，所有患儿身高都有不同程度增加。平均共增高8．3±1．2cm，身高落后值（SDS）由治疗前的-5．51±0．94减少到治疗后的-4．20±0．96。在6个月的用药期，13例患儿身高增长速率明显增加，为16．6±2．4cm·y-1，与治疗前24±0.6cm·y-1相比增加非常明显（P＜0．001）。除少数患者用药初期与注射部位皮肤出现暂时性红斑外，未见其他不良反应。Thirteen cases of growth hormone deficiency were treated for 6 months with authentic recombinant human growth hormone (r-hGH). The height of all cases was increased in different degrees, with 8. 3 ± 1. 2cm in average. The height velocity SD score was decreased from - 5. 51 ± O. 94 to - 4. 20± 0. 96 before and after the therapy. The height growing velocity of all l3 chi1dren was increased obviously during the 6-month treatment (16. 6 ± 2. 4cm. y-1 ),as compared with the pretherapeutic state (2. 4 ± 0. 6cm. y-1,P<0. 001 ). No side effects were observed except that temporary erythema at the site of injection might be found in the initial stage of the treatment in minority of cases. It indicates that r-hGH has striking curative effects and is safe to use.

关 键 词：垂体性 侏儒症 重组人生长激素 治疗 

分 类 号：R584.210.5[医药卫生—内分泌]